Genetic Analysis operates in medical technology. The company conducts research and development in the field of diagnostics, with the main focus on the human microbiome. The technology is based on the company's research platform and the products are used, for example, for testing and analysis of bacteria and other viruses. The largest operations are in the Nordic market.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Avanza Bank AB | 27,73 | 27,73 | 2022-12-28 |
| Bio-Rad Luxembourg S.À.R.L. | 21,26 | 21,26 | 2022-12-28 |
| Nordnet Bank AB | 6,20 | 6,20 | 2022-12-28 |
| Biohit Oyj | 5,71 | 5,71 | 2022-12-28 |
| Negma Group Ltd. | 4,63 | 4,63 | 2021-10-01 |
| Norsk Innovasjonskapital | 3,28 | 3,28 | 2021-10-01 |
| Molver AS | 2,59 | 2,59 | 2022-12-28 |
| Leif Jørgen Moger | 2,22 | 2,22 | 2022-12-28 |
| S. Munkhaugen AS | 1,94 | 1,94 | 2022-12-28 |
| Jama Holding AS | 1,72 | 1,72 | 2022-12-28 |
2023-08-30 Delårsrapport 2023-Q2